• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Quinupristin-dalfopristin nonsusceptibility in pneumococci from sickle cell disease patients.镰状细胞病患者肺炎球菌对奎奴普丁-达福普汀不敏感
Antimicrob Agents Chemother. 2007 Jan;51(1):386-9. doi: 10.1128/AAC.01016-06. Epub 2006 Oct 23.
2
Activity of quinupristin-dalfopristin in invasive isolates of Streptococcus pneumoniae from Italy.奎奴普丁-达福普汀对来自意大利的肺炎链球菌侵袭性分离株的活性。
Clin Microbiol Infect. 2001 Sep;7(9):503-6. doi: 10.1046/j.1198-743x.2001.00298.x.
3
Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin).一种酮内酯（HMR 3647）、一种链阳菌素（奎奴普丁-达福普汀）、一种大环内酯（红霉素）和一种林可酰胺（克林霉素）的抗肺炎球菌活性。
Antimicrob Agents Chemother. 1998 Apr;42(4):945-6. doi: 10.1128/AAC.42.4.945.
4
In vitro activity of quinupristin/dalfopristin against erythromycin-susceptible and erythromycin-resistant Streptococcus pneumoniae.奎奴普丁/达福普汀对红霉素敏感及耐药肺炎链球菌的体外活性
Eur J Clin Microbiol Infect Dis. 1998 Sep;17(9):662-5. doi: 10.1007/BF01708352.
5
Comparative in-vitro activity of quinupristin/dalfopristin (RP 59500) tested against penicillin-and macrolide-resistant pneumococci by the Etest.
J Antimicrob Chemother. 1996 Sep;38(3):553-5. doi: 10.1093/jac/38.3.553.
6
Comparative activity of linezolid, quinupristin-dalfopristin and newer quinolones against Streptococcus pneumoniae.
Int J Antimicrob Agents. 2003 Mar;21(3):289-91. doi: 10.1016/s0924-8579(02)00357-6.
7
Erythromycin resistance among invasive pneumococci in Scotland, 1994-2003.
Br J Biomed Sci. 2005;62(1):28-30. doi: 10.1080/09674845.2005.11732684.
8
In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations.泰利霉素、利奈唑胺和奎奴普丁-达福普汀对因核糖体突变而对大环内酯类耐药的肺炎链球菌的体外活性。
Antimicrob Agents Chemother. 2004 Aug;48(8):3169-71. doi: 10.1128/AAC.48.8.3169-3171.2004.
9
Erythromycin resistance in invasive serotype 14 pneumococci is highly related to clonal type.侵袭性血清型14肺炎球菌对红霉素的耐药性与克隆类型高度相关。
J Med Microbiol. 2004 Nov;53(Pt 11):1101-1103. doi: 10.1099/jmm.0.45737-0.
10
Serotypes, Clones, and Mechanisms of Resistance of Erythromycin-Resistant Streptococcus pneumoniae Isolates Collected in Spain.西班牙收集的耐红霉素肺炎链球菌分离株的血清型、克隆及耐药机制
Antimicrob Agents Chemother. 2007 Sep;51(9):3240-6. doi: 10.1128/AAC.00157-07. Epub 2007 Jul 2.

本文引用的文献

1
Identification of a Candidate Streptococcus pneumoniae core genome and regions of diversity correlated with invasive pneumococcal disease.鉴定肺炎链球菌候选核心基因组及与侵袭性肺炎球菌病相关的多样性区域。
Infect Immun. 2006 Aug;74(8):4766-77. doi: 10.1128/IAI.00316-06.
2
Cephalosporin-resistant pneumococci and sickle cell disease.耐头孢菌素肺炎球菌与镰状细胞病
Emerg Infect Dis. 2005 Aug;11(8):1192-6. doi: 10.3201/eid1108.050152.
3
The streptogramin antibiotics: update on their mechanism of action.链阳菌素类抗生素：作用机制的最新进展
Expert Opin Investig Drugs. 1998 Apr;7(4):591-9. doi: 10.1517/13543784.7.4.591.
4
Bayesian Monte Carlo uncertainty analysis of human health risks from animal antimicrobial use in a dynamic model of emerging resistance.在新兴抗药性动态模型中，对动物抗菌药物使用所带来的人类健康风险进行贝叶斯蒙特卡洛不确定性分析。
Risk Anal. 2004 Oct;24(5):1153-64. doi: 10.1111/j.0272-4332.2004.00516.x.
5
Tolerance to vancomycin in pneumococci: detection with a molecular marker and assessment of clinical impact.
J Infect Dis. 2004 Oct 15;190(8):1481-7. doi: 10.1086/424467. Epub 2004 Sep 9.
6
Nontherapeutic use of antimicrobial agents in animal agriculture: implications for pediatrics.抗菌剂在畜牧业中的非治疗性使用：对儿科的影响。
Pediatrics. 2004 Sep;114(3):862-8. doi: 10.1542/peds.2004-1233.
7
In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations.泰利霉素、利奈唑胺和奎奴普丁-达福普汀对因核糖体突变而对大环内酯类耐药的肺炎链球菌的体外活性。
Antimicrob Agents Chemother. 2004 Aug;48(8):3169-71. doi: 10.1128/AAC.48.8.3169-3171.2004.
8
Treatment of multifocal vancomycin-resistant Enterococcus faecium osteomyelitis in sickle cell disease: a preliminary report.镰状细胞病中多灶性耐万古霉素粪肠球菌骨髓炎的治疗：初步报告。
Am J Orthop (Belle Mead NJ). 2003 Oct;32(10):505-9.
9
Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination.在青霉素预防、抗生素耐药性和23价肺炎球菌多糖疫苗接种时代，镰状细胞病患儿的侵袭性肺炎球菌感染
J Pediatr. 2003 Oct;143(4):438-44. doi: 10.1067/S0022-3476(03)00331-7.
10
Quinupristin-dalfopristin resistance in Streptococcus pneumoniae: novel L22 ribosomal protein mutation in two clinical isolates from the SENTRY antimicrobial surveillance program.肺炎链球菌对奎奴普丁-达福普汀的耐药性：来自哨兵抗菌监测项目的两株临床分离株中核糖体蛋白L22的新突变
Antimicrob Agents Chemother. 2003 Aug;47(8):2696-8. doi: 10.1128/AAC.47.8.2696-2698.2003.

镰状细胞病患者肺炎球菌对奎奴普丁-达福普汀不敏感

Quinupristin-dalfopristin nonsusceptibility in pneumococci from sickle cell disease patients.

作者信息

Obert Caroline A, Miller Martha L, Montgomery Jeremy, Adamkiewicz Thomas, Tuomanen Elaine I

机构信息

Department of Infectious Diseases, St. Jude Children's Research Hospital, 332 North Lauderdale St., Memphis, TN 38105-2794, USA.

出版信息

Antimicrob Agents Chemother. 2007 Jan;51(1):386-9. doi: 10.1128/AAC.01016-06. Epub 2006 Oct 23.

DOI:10.1128/AAC.01016-06
PMID:17060526
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1797651/
Abstract

Sickle cell disease (SCD) is a risk factor for fatal pneumococcal infection. Nonsusceptibilty to quinupristin-dalfopristin (Q-D) was absent from 105 non-SCD-associated pneumococcal isolates but was present in 33/148 (22%) SCD-associated isolates. One-third of the isolates harbored a known resistance mechanism. Q-D is not optimal for use for the treatment of pneumococcal infection in SCD patients.

摘要

镰状细胞病（SCD）是致命性肺炎球菌感染的一个危险因素。105株非SCD相关肺炎球菌分离株对奎奴普丁-达福普汀（Q-D）不耐药，但148株SCD相关分离株中有33株（22%）耐药。三分之一的分离株具有已知的耐药机制。Q-D并非治疗SCD患者肺炎球菌感染的最佳药物。